Low
NA
IV$$$$$$ PO$$$$$
IV formulation contains sulfobutyl ether beta-cyclodextrin (SBECD) which may accumulate in renal insufficiency
Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing
In most patients, oral therapy has not been recommended as initial therapy for treatment; it has been recommended to convert parenteral to oral therapy only after significant clinical improvement has been observed
In pediatric patients <12 years, bioequivalence between the oral tablet and suspension has not been determined; due to possible shortened gastric transit time in infants and children, absorption of tablets may be different than adults; it is recommended that infants and children <12 years only receive oral suspension formulation
Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity (discuss with ID)
Monitor QTc interval in patients at elevated risk
Monitor hepatic profile
QTc prolongation
Hepatic enzyme abnormalities
Rash: up to 20%
GI upset
Visual disturbances commonly associated with treatment, usually reversible with duration of use < 28 days
Many via CYP450 - suggest review interactions with pharmacist
Risk when combining with other QTc prolonging agents
Antimicrobial class: Triazole antifungal, second generation
Average serum half life: Variable and dose dependent
Route of Elimination: Urine (<2% as unchanged drug)
